CD74 and prostate carcinoma: Additionally, antibody-based agents such as [111In]In-NLS-trastuzumab for breast cancer (25), [111In]In-anti-CD74 for B-cell lymphoma (26), and [111In]In-J591 (27) for prostate cancer showed strong therapeutic efficacy in preclinical studies.